Galcanezumab (Emgality) prior authorization at CareFirst BCBS
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
CareFirst BCBS requires prior-authorization documentation for Galcanezumab (Emgality): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
CareFirst BCBS reviews Galcanezumab (Emgality) prior authorizations against its medical policy . CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- CareFirst BCBS's medical policy URL referenced in the cover letter
CareFirst BCBS's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- DC/MD/VA cross-jurisdiction issues
- Step therapy on specialty drugs via CVS Caremark
- Behavioral health network adequacy
- BlueChoice HMO referral denials
Galcanezumab (Emgality)-specific denial patterns and context
Across payers (not just CareFirst BCBS), Galcanezumab (Emgality)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring 2+ older oral preventives (topiramate, propranolol, amitriptyline)
- Migraine days threshold (≥4 monthly for episodic, ≥15 for chronic)
- Indication restriction (episodic vs chronic vs cluster)
Brand: Emgality. CGRP ligand monoclonal antibody. FDA-approved for migraine prevention (episodic and chronic) and episodic cluster headache.
Manufacturer patient-assistance program: Lilly Cares Foundation — relevant when a CareFirst BCBS denial sticks and the patient needs bridge access while appealing.
How CareFirst BCBS approaches Biologic drugs (mAbs and biosimilars) PAs
CareFirst BCBS's Biologic drugs (mAbs and biosimilars) reviewer typically anchors Galcanezumab prior-auth decisions on step therapy on specialty drugs via cvs caremark. Pharmacy-benefit review for Galcanezumab at CareFirst BCBS is routed through CVS Caremark. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. CareFirst BCBS's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. CareFirst BCBS is domiciled in MD, so unresolved appeals escalate to the MD insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for Maryland, DC, and northern Virginia (~3.
If the PA is denied
CareFirst BCBS gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://provider.carefirst.com) with the same packet plus a peer-reviewed citation supporting Galcanezumab (Emgality)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a CareFirst BCBS denial on DenialHelp.
Contact CareFirst BCBS
- Provider portal: https://provider.carefirst.com
Frequently asked questions
What documentation does CareFirst BCBS need for Galcanezumab (Emgality) prior auth?
CareFirst BCBS's typical PA packet for Galcanezumab (Emgality): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at CareFirst BCBS?
Standard Galcanezumab (Emgality) PA decisions at CareFirst BCBS: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does CareFirst BCBS most often reject Galcanezumab (Emgality) for?
Across CareFirst BCBS's book the common rejection patterns include: DC/MD/VA cross-jurisdiction issues; Step therapy on specialty drugs via CVS Caremark; Behavioral health network adequacy. For Galcanezumab (Emgality) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does CareFirst BCBS typically require before approving Galcanezumab?
CareFirst BCBS's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Galcanezumab, attach the specific disease-activity instrument CareFirst BCBS accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through CVS Caremark. External-review escalation for CareFirst BCBS fully-insured policies sits with the MD insurance department.
How do I prep for a peer-to-peer with CareFirst BCBS on Galcanezumab (Emgality)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Galcanezumab (Emgality) PA packet
Open ApprovalHelp — generate a Galcanezumab (Emgality) prior-auth packet tailored to CareFirst BCBS's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com